The Brief
What we’re tracking.
Quick reads from the science of feeling better, longer — pulled from the data we look at every quarter, the methodology we build on, and the regulatory shifts shaping what’s next.
Data · Cellular energy
Why NAD+ falls 50% by age 70.
Tissue NAD+ decline from age 30 to 70 — and the floor below which mitochondrial output stops keeping up.
Primer · Methodology
Biological age, explained.
The methylation, phenotypic, and pace-of-aging clocks behind longevity intelligence — and which one Halo uses to project where you actually stand.
Current event · Regulatory
The 2026 FDA peptide review.
PCAC convenes July 23–24 to reclassify seven peptides — including BPC-157, KPV, and TB-500. What changes for your protocol when the verdict lands.
Editorial note
The Brief publishes quarterly. We don’t cover everything — only what changes the protocol. New issue when the data warrants it.